Spots Global Cancer Trial Database for melanoma
Every month we try and update this database with for melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan | NCT03165422 | Melanoma | Non-Interventio... | 18 Years - | Bristol-Myers Squibb | |
| A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma | NCT00585000 | Melanoma | CP-675,206 | 18 Years - | AstraZeneca | |
| Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation | NCT01959633 | Melanoma | Vemurafenib Peg-interferon Cobimetinib | 18 Years - | Fondazione Melanoma Onlus | |
| Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma | NCT00110994 | Cancer Melanoma | Sorafenib (Nexa... Placebo Dacarbazine | 18 Years - | Bayer | |
| Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer | NCT00095108 | Melanoma Kidney Neoplasm... Metastases | Recombinant Hum... | 18 Years - | ZymoGenetics | |
| A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma | NCT00434252 | Melanoma | bevacizumab carboplatin paclitaxel placebo | 18 Years - | Genentech, Inc. | |
| Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program | NCT01772771 | Glioma Hematopoietic a... Malignant Solid... Melanoma Sarcoma | Biospecimen Col... Genetic Testing Medical Chart R... | - | M.D. Anderson Cancer Center | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | NCT02032810 | Melanoma Skin Cancer | Panobinostat Ipilimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | NCT04198766 | Solid Tumor Non-Small Cell ... Melanoma Head and Neck C... Gastric Cancer Renal Cell Carc... Urothelial Carc... | INBRX-106 - Hex... Pembrolizumab 2... Pembrolizumab 4... | 18 Years - | Inhibrx, Inc. | |
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | NCT02807844 | Triple Negative... Pancreatic Carc... Melanoma Endometrial Car... | MCS110 PDR001 | 18 Years - | Novartis | |
| A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | NCT03470922 | Melanoma | Relatlimab Nivolumab | 12 Years - | Bristol-Myers Squibb | |
| Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression | NCT00835419 | Melanoma | P276-00 | 18 Years - | Piramal Enterprises Limited | |
| A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer | NCT01021059 | Melanoma Carcinoma, Rena... | rh IL-15 | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | NCT05668585 | Solid Tumors Melanoma NSCLC CRC ATC | CFT1946 Trametinib Cetuximab | 18 Years - | C4 Therapeutics, Inc. | |
| Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma | NCT00896480 | Melanoma | Immunotherapeut... | 18 Years - | GlaxoSmithKline | |
| Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma | NCT00847522 | Cancer | Fluorescein | 18 Years - | University of Utah | |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors | NCT04572451 | Melanoma Carcinoma, Rena... Unresectable So... | nivolumab BMS-986253 Stereotactic Bo... | 18 Years - | University of Pittsburgh | |
| A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma | NCT01970358 | Melanoma | Poly-ICLC Peptides | 18 Years - | Dana-Farber Cancer Institute | |
| Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integrated Dermoscopy and Comparison With Histology (DERMOCTAV) | NCT05340543 | Cutaneous Tumor Optical Coheren... Basal Cell Carc... Squamous Cell C... Melanoma | Confocal optica... | 18 Years - | Ramsay Générale de Santé | |
| Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma | NCT01721772 | Melanoma | BMS-936558 (Niv... Placebo matchin... Dacarbazine Placebo matchin... | 18 Years - | Bristol-Myers Squibb | |
| Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma | NCT01009515 | Melanoma | Paclitaxel, car... | 18 Years - | New Mexico Cancer Care Alliance | |
| A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | NCT00600496 | Breast Cancer Breast Neoplasm... Colon Cancer Colonic Cancer Colon Neoplasms Lung Cancer Melanoma Kidney Cancer | AZD6244 Dacarbazine Erlotinib Docetaxel Temsirolimus | 18 Years - 130 Years | AstraZeneca | |
| Genetically-informed Therapies for Patients With Metastatic Cancer | NCT02000739 | Metastatic Canc... | Genetically Inf... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | NCT04068896 | Pancreatic Canc... Metastatic Cast... Bladder Cancer Melanoma Non-small Cell ... Colorectal Canc... Gastric Cancer Esophageal Canc... Ovarian Cancer Head Neck Squam... Prostate Cancer | NGM120 NGM120 NGM120 NGM120 NGM120 NGM120 Placebo | 18 Years - | NGM Biopharmaceuticals, Inc | |
| Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome | NCT00003601 | Melanoma (Skin) | fenretinide tretinoin | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | NCT05549297 | Advanced Melano... | Tebentafusp Tebentafusp wit... Investigators C... | 18 Years - | Immunocore Ltd | |
| Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | NCT02425306 | Melanoma | 6MHP Montanide ISA-5... polyICLC Cyclophosphamid... | 18 Years - | University of Virginia | |
| PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study | NCT01266096 | Newly Diagnosed... Malignant Brain... | PET scan with 1... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Adoptive Therapy Using Antigen-Specific CD4 T-Cells | NCT02210104 | Melanoma Sarcoma | Ipilimumab Cyclophosphamid... CD4+ T cells | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | NCT06346067 | Advanced or Met... | Naporafenib Dacarbazine Temozolomide Trametinib | 18 Years - 99 Years | Erasca, Inc. | |
| Genetically-informed Therapies for Patients With Metastatic Cancer | NCT02000739 | Metastatic Canc... | Genetically Inf... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma. | NCT02821182 | Melanoma | stereotactic bo... | 18 Years - | University Hospital, Ghent | |
| Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients | NCT01308294 | Melanoma | 2 vaccine injec... 2 vaccine injec... 2 "vaccine inje... | 18 Years - | Centre Hospitalier Universitaire Vaudois | |
| Melanoma Molecular Profiling Analysis | NCT00889980 | Melanoma | Biospecimen ban... | 12 Years - | University of Pittsburgh | |
| LATe TreatmENT Related Toxicity in Melanoma (LATENT) | NCT06414343 | Melanoma | Observational -... | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Cytokine-induced Killer Study for Patients With Stage II Melanoma | NCT02498756 | Melanoma | Cytokine-induce... Ipilimumab | 18 Years - 80 Years | The First People's Hospital of Changzhou | |
| A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | NCT03999749 | Melanoma | Ipilimumab Nivolumab Tocilizumab | 18 Years - | NYU Langone Health | |
| Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma | NCT02626962 | Uveal Melanoma | ipilimumab Nivolumab | 18 Years - 99 Years | Grupo Español Multidisciplinar de Melanoma | |
| Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases | NCT02621515 | Melanoma Brain Metastasi... | Nivolumab | 18 Years - | University Medical Center Groningen | |
| Does the Aid of MelaFind Affect Clinical Management Decisions | NCT01387581 | Melanoma | - | MELA Sciences, Inc. | ||
| Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom | NCT03448497 | Melanoma | Non-interventio... | 18 Years - | Bristol-Myers Squibb | |
| Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | NCT02425306 | Melanoma | 6MHP Montanide ISA-5... polyICLC Cyclophosphamid... | 18 Years - | University of Virginia | |
| Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma | NCT00847522 | Cancer | Fluorescein | 18 Years - | University of Utah | |
| Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes | NCT02416336 | Melanoma Head and Neck C... Breast Cancer | Sentinella Intr... | - | Oncovision Inc | |
| Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma | NCT04197882 | Melanoma | OrienX010 Combi... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | NCT04609566 | Melanoma Non-small Cell ... Squamous Cell C... | brentuximab ved... pembrolizumab | 18 Years - | Seagen Inc. | |
| A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | NCT05229601 | Soft Tissue Sar... Renal Cell Carc... Uterine Carcino... Hepatocellular ... Head and Neck S... Melanoma | HFB301001 | 18 Years - | HiFiBiO Therapeutics | |
| Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma | NCT02659540 | Melanoma | Nivolumab Ipilimumab Radiotherapy | 18 Years - | Ludwig Institute for Cancer Research | |
| The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany | NCT03205722 | Melanoma | Non-Interventio... | 18 Years - | Bristol-Myers Squibb | |
| XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation | NCT05275374 | Cancer BRAF V600 Mutat... Melanoma Colorectal Canc... Thyroid Cancer Nonsmall Cell L... | XP-102 Trametinib | 18 Years - | Xynomic Pharmaceuticals, Inc. | |
| Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | NCT04144140 | Lymphoma Advanced Solid ... | E7766 | 18 Years - | Eisai Inc. | |
| Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | NCT03454035 | Tumor, Solid Pancreatic Canc... Melanoma | Ulixertinib Palbociclib | 18 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center | |
| Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma | NCT00107718 | Melanoma | SB-485232 | 18 Years - | GlaxoSmithKline | |
| Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. | NCT05831995 | Advanced Solid ... RAS Mutation RAF Mutation NF1 Mutation | ABM-168 | 18 Years - | ABM Therapeutics Corporation | |
| Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF) | NCT00809588 | Melanoma | Autologous, let... | 18 Years - | Dana-Farber Cancer Institute | |
| In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma | NCT02759536 | Melanoma Boron Neutron C... | Boronophenylala... | 18 Years - | The Third Xiangya Hospital of Central South University | |
| Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer | NCT01149343 | Melanoma | Immunotherapeut... | 18 Years - | GlaxoSmithKline | |
| Impact of Telemonitoring for the Management of Side Effects in Patients With Melanoma, Lung or Renal Cancer, Treated With Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy | NCT04605146 | Melanoma Lung Cancer Renal Cancer | Tele-monitoring | 18 Years - | Hospices Civils de Lyon | |
| Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | NCT04598009 | Melanoma Stage ... Melanoma Stage ... | Binimetinib Imatinib | 18 Years - | University of California, San Francisco | |
| Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma | NCT01152788 | Melanoma | rIL-21 Dacarbazine | 18 Years - | Canadian Cancer Trials Group | |
| Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | NCT04038619 | Colitis Diarrhea Malignant Genit... Melanoma Lung Cancer Ovarian Cancer Uterine Cancer Breast Cancer Cervical Cancer | Fecal Microbiot... Loperamide | 18 Years - | M.D. Anderson Cancer Center | |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | NCT02568267 | Breast Cancer Cholangiocarcin... Colorectal Canc... Head and Neck N... Lymphoma, Large... Melanoma Neuroendocrine ... Non-Small Cell ... Ovarian Cancer Pancreatic Canc... Papillary Thyro... Primary Brain T... Renal Cell Carc... Sarcomas Salivary Gland ... Adult Solid Tum... | Entrectinib | 18 Years - | Hoffmann-La Roche | |
| Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma | NCT01216436 | Metastatic Mela... | Vaccination wit... | 18 Years - | Duke University | |
| Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma | NCT01944709 | Melanoma | Dendritic cell ... | 18 Years - | Cantonal Hospital of St. Gallen | |
| PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) | NCT00043368 | Melanoma Breast Neoplasm... Carcinoma, Rena... Lymphoma, T-Cel... Carcinoma, Non-... | PF-3512676 | 18 Years - | Pfizer | |
| Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab | NCT02977052 | Malignant Melan... | Ipilimumab Nivolumab Surgery Blood for PBMCs Biopsies | 18 Years - | The Netherlands Cancer Institute | |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | NCT03336606 | Head and Neck C... Head and Neck S... Melanoma Cell Cancer, Sq... Carcinoma, Squa... | MEDI0562 | 18 Years - | Providence Health & Services | |
| A Study of ASP1951 in Subjects With Advanced Solid Tumors | NCT03799003 | Advanced Solid ... | ASP1951 pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases | NCT03754140 | Melanoma In-Transit Meta... | Polidocanol Inj... | 18 Years - | Melanoma Institute Australia | |
| Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma | NCT00200577 | Melanoma | TIL + IL2 | - 75 Years | Nantes University Hospital | |
| Melanoma Vaccine With Peptides and Leuprolide | NCT00254397 | Melanoma | Leuprolide GP100: 209-217(... MAGE-3 Peptide | 18 Years - | M.D. Anderson Cancer Center | |
| The Incidence of Breast and Other Cancers Among Female Flight Attendants | NCT00342407 | Thyroid Cancer Breast Cancer Non-Melanoma Sk... Melanoma | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | NCT04261439 | In Escalation: ... In Expansion: M... | NIZ985 Spartalizumab Tislelizumab | 18 Years - | Novartis | |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | NCT03190174 | Ewing Sarcoma PEComa Epithelioid Sar... Desmoid Tumor Chordoma Non Small Cell ... Urothelial Carc... Melanoma Renal Cell Carc... Squamous Cell C... Hepatocellular ... Classical Hodgk... Colorectal Canc... MTOR Activating... | Nab-Rapamycin Nivolumab | 12 Years - | Sarcoma Oncology Research Center, LLC | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy | NCT00257205 | Melanoma | dacarbazine CP-675,206 temozolomide | 18 Years - | AstraZeneca | |
| Melanomas Excised in Primary Care vs Secondary Care Excision | NCT03169036 | Melanoma | - | University of Aberdeen | ||
| A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | NCT04731467 | Solid Tumor Non Small Cell ... Pancreatic Canc... Ovarian Cancer Papillary Thyro... Melanoma Colorectal Aden... | CM-24 and Nivol... CM-24, Nivoluma... CM-24, Nivoluma... Nivolumab, Nab ... Nivolumab and N... | 18 Years - | Purple Biotech Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
